Semaglutide vs AOD-9604

Semaglutide and AOD-9604 represent distinct approaches to metabolic research. Semaglutide, a GLP-1 receptor agonist, is supported by extensive clinical trial programs (STEP, SUSTAIN) involving thousands of participants, with FDA approval for type 2 diabetes, chronic weight management, and non-cirrhotic MASH. In contrast, AOD-9604 is a modified fragment of human growth hormone developed at Monash University, targeting lipolysis without growth-promoting effects. While Semaglutide has a robust evidence base from large-scale human trials, AOD-9604 underwent six randomized, double-blind, placebo-controlled obesity trials in the early 2000s, showing modest fat loss. Their mechanisms, safety profiles, and research applications diverge significantly, making this comparison essential for informed peptide selection.

Semaglutide is a synthetic GLP-1 receptor agonist with 94% sequence homology to human GLP-1 (molecular weight ~4113.6 g/mol, formula C187H291N45O59). Developed by Novo Nordisk and first FDA-approved on December 5, 2017, it mimics endogenous incretin hormones to stimulate insulin secretion, suppress glucagon release, and delay gastric emptying. Its approval for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH reflects a broad therapeutic index. The evidence base is exceptionally strong, derived from the STEP and SUSTAIN trial programs involving thousands of participants, demonstrating significant weight loss, improved glycemic control, and reduced cardiovascular risk. Notably, no generic semaglutide exists, and the FDA has issued warnings about counterfeit products. Researchers should consider its potent, systemic effects when designing studies.

AOD-9604 is a modified peptide fragment corresponding to amino acids 177-191 of human growth hormone, with an N-terminal tyrosine added (Tyr-hGH(177-191)). Developed at Monash University, Australia, it retains the lipolytic properties of HGH—promoting fat breakdown—while eliminating growth-promoting and diabetogenic effects. This selectivity makes it a unique tool for studying fat metabolism without influencing IGF-1 or blood glucose. The evidence base includes six randomized, double-blind, placebo-controlled human clinical trials for obesity conducted in the early 2000s, which reported modest but consistent fat loss (~5% body weight) and a side effect profile indistinguishable from placebo. The FDA granted AOD-9604 GRAS status for food use in 2014, though clinical development for obesity was discontinued. Researchers should note its targeted mechanism and limited but controlled human data.

While both peptides are investigated in metabolic research, their applications diverge. Semaglutide is primarily studied for weight management, metabolic health, and cardiovascular outcomes, leveraging its GLP-1 receptor agonism to influence appetite, glucose homeostasis, and systemic inflammation. AOD-9604, in contrast, is specifically explored for fat loss without broader metabolic effects, making it relevant for studies on adipose tissue regulation and lipolysis. Overlap exists in obesity research, but Semaglutide addresses multiple metabolic pathways, whereas AOD-9604 offers a more targeted approach. Researchers should align their choice with the specific hypothesis: Semaglutide for comprehensive metabolic modulation, AOD-9604 for isolated fat metabolism investigations.

Semaglutide's safety profile is well-characterized from large-scale trials. Common adverse effects (≥5% incidence) include nausea, vomiting, diarrhea, abdominal pain, and constipation, which are typically dose-dependent and transient. Additional reports include upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, and fatigue. Serious but rare events include pancreatitis, gallbladder disease, and severe allergic reactions (hives, swelling, difficulty breathing). In contrast, AOD-9604's clinical trials showed a side effect profile virtually indistinguishable from placebo, with mild injection site reactions (redness, pain, small welts) being the most common complaint. Mild headaches or flushing were reported in a small percentage of users. Researchers should weigh Semaglutide's broader, more documented risk profile against AOD-9604's favorable tolerability in controlled settings.